Nice informative post.
However, you got the drug mechanism wrong. Both erenumab and fremanezumab are antibodies. They are not reducing CRGP levels, but are binding to the protein and therefore reduce it's capability to interact with its natural ligand. I.e., they partially inactivate it.
and:
@OriginalWorks
To call @OriginalWorks, simply reply to any post with @originalworks or !originalworks in your message!
Ok, fair point - but the point of this article was not to explain the MoA of these compounds, that would be a whole post in itself, and is why I glosssed over it in less than a paragraph
Cheers